GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Poseida Therapeutics
Poseida Therapeutics is a biotech company developing cell and gene therapies. Its stock price represents a venture bet on its scientific developments. The stock price reflects high volatility and dependence on clinical trial data and partnerships with pharmaceutical giants.
Share prices of companies in the market segment - Oncology cell gene therapy
Poseida Therapeutics is a biotech company developing next-generation cell and gene therapies for the treatment of cancer and rare diseases. We've categorized it under "Oncology: Cell Therapy." The chart below shows how the market values this cutting-edge biotech sector.
Broad Market Index - GURU.Markets
Poseida Therapeutics is a biotech company developing next-generation cell and gene therapies for the treatment of cancer and rare diseases. We've categorized it under "Oncology: Cell Therapy." The chart below shows how the market values this cutting-edge biotech sector.
Change in the price of a company, segment, and market as a whole per day
PSTX - Daily change in the company's share price Poseida Therapeutics
For Poseida Therapeutics, Inc., a cell and gene therapy company, daily volatility reflects sensitivity to clinical trial data. This metric is an important element in assessing risk in this innovative field.
Daily change in the price of a set of shares in a market segment - Oncology cell gene therapy
Poseida Therapeutics is a biopharmaceutical company developing next-generation cell and gene therapies for cancer treatment. The cell therapy sector is one of the most advanced and volatile in biotech. The chart below reflects the average fluctuations in this industry, serving as a benchmark for valuing PSTX stock.
Daily change in the price of a broad market stock, index - GURU.Markets
Poseida Therapeutics is a biotech company working on cell therapy. Its shares are a bet on scientific breakthroughs. Their extreme volatility, driven by research data, is part of the dynamics of the innovation sector, which impacts the entire market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Poseida Therapeutics
Poseida Therapeutics' year-to-date performance is a story of cell and gene therapy development. Its 12-month market cap is entirely dependent on clinical trial data. Its valuation is a bet that its cutting-edge technologies, such as booster molecules, will make cell therapy safer and more effective.
Annual dynamics of market capitalization of the market segment - Oncology cell gene therapy
As an early-stage biotech, Poseida is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about its cell and gene therapy platform. Its stock price will reflect investors' speculative belief in its potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Poseida Therapeutics is a company at the forefront of gene therapy, and its shares thrive on lab news. Its year-over-year performance relative to the market isn't about economics, but rather about hope for a revolution in disease treatment. Success in trials can boost the stock, demonstrating a complete disconnect from overall market sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Poseida Therapeutics
Poseida is an oncology company developing cell and gene therapies. Being in the clinical stage, its monthly valuation is entirely dependent on news. Trial results confirming the viability of its unique technologies are the main driver.
Monthly dynamics of market capitalization of the market segment - Oncology cell gene therapy
Poseida Therapeutics is a biotechnology company developing next-generation cell and gene therapies with a focus on oncology and rare diseases. The chart below shows the overall dynamics of the cell and gene therapy sector, one of the most advanced and capital-intensive in modern medicine.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of biotech companies working at the cutting edge of science, such as cell therapy, often move independently of the market. The chart below shows the overall sentiment. Does Poseida Therapeutics live in a world of its own, where development news trumps overall market trends?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Poseida Therapeutics
The weekly performance of Poseida, a cell and gene therapy company, reflects the cutting edge of science. Shares are reacting sharply to clinical trial data from their innovative treatments for cancer and rare diseases.
Weekly dynamics of market capitalization of the market segment - Oncology cell gene therapy
Poseida Therapeutics is a pioneer in cell and gene therapy, a cutting-edge but highly risky field of medicine. The chart will show how the market values its complex technologies compared to the biotech sector, reflecting investor confidence in its ability to achieve breakthroughs in cancer treatment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Poseida Therapeutics is a biotech company working in the cutting-edge field of cell therapy. Shares of such innovative companies often move independently of the market. This chart will help you understand: does Poseida exist in its own world of clinical trials, or does the overall market environment influence its stock price?
Market capitalization of the company, segment and market as a whole
PSTX - Market capitalization of the company Poseida Therapeutics
Poseida's market capitalization chart tells the story of a biotech company developing cell and gene therapies. Its volatile chart reflects the scientific potential of its platforms and partnerships with major pharmaceutical companies. Its dynamics reflect the market's assessment of its ability to develop next-generation drugs for cancer and rare diseases.
PSTX - Share of the company's market capitalization Poseida Therapeutics within the market segment - Oncology cell gene therapy
Poseida Therapeutics is a pioneer in cell and gene therapy. Its market capitalization in its leading biotech segment reflects the high expectations for its platform. The chart below illustrates how the market views the potential of its technologies for treating serious diseases.
Market capitalization of the market segment - Oncology cell gene therapy
Poseida Therapeutics is a biotech company developing cell and gene therapies for the treatment of cancer and rare diseases. The chart below shows the market capitalization of this cutting-edge sector. Its volatility reflects both the enormous potential of these technologies and the high risks associated with their development.
Market capitalization of all companies included in a broad market index - GURU.Markets
Poseida Therapeutics is a cell and gene therapy company. Its market cap reflects the potential of its cutting-edge technologies to offer new treatments for cancer and rare diseases. Its volatility reflects the enormous promise and risks of being at the forefront of medicine.
Book value capitalization of the company, segment and market as a whole
PSTX - Book value capitalization of the company Poseida Therapeutics
Poseida Therapeutics' book value is derived from its equity and patents for cutting-edge genetic engineering platforms for creating next-generation cell therapies. This provides a tangible, scientific foundation for safer and more effective cancer treatment. How has this innovative biotech asset changed? The chart below shows its dynamics.
PSTX - Share of the company's book capitalization Poseida Therapeutics within the market segment - Oncology cell gene therapy
Poseida Therapeutics is a pioneer in cell and gene therapy, which requires advanced manufacturing facilities. The chart shows the share of these unique and expensive tangible assets, reflecting the physical foundation of its high-tech platform.
Market segment balance sheet capitalization - Oncology cell gene therapy
Poseida, a cell therapy company, is a capital-intensive business. This requires owning cutting-edge R&D centers and building its own production facilities. The BCap_Seg chart for the biotech sector shows that developing breakthrough technologies requires a significant financial base.
Book value of all companies included in the broad market index - GURU.Markets
Poseida's capital comes from its cutting-edge genetic engineering platforms (such as piggyBac) for developing cancer cell therapies. The company's assets include its intellectual property, patents, and manufacturing facilities. The chart below shows the net worth of this oncology innovator.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Poseida Therapeutics
Poseida Therapeutics is a gene and cell therapy company. Its balance sheet represents the value of its unique technology platform. Its market capitalization represents investors' hopes for breakthrough cancer treatments. The chart below shows how high expectations are for the cutting-edge advances in medical science.
Market to book capitalization ratio in a market segment - Oncology cell gene therapy
Poseida Therapeutics is a biotech company developing advanced cell and gene therapies. Its high valuation reflects the breakthrough potential of its scientific platforms, which could offer new treatments for cancer and rare diseases.
Market to book capitalization ratio for the market as a whole
Poseida Therapeutics operates in the cutting-edge field of cell and gene therapy. Its value is derived almost entirely from intangible assets—unique technologies and patents. The chart helps assess the premium for breakthrough but high-risk scientific developments compared to the market average.
Debts of the company, segment and market as a whole
PSTX - Company debts Poseida Therapeutics
Poseida Therapeutics, a biotech company developing cell and gene therapies, uses capital to fund its complex and expensive clinical programs. This chart shows how the company is raising significant funds to advance its cutting-edge technologies, which could offer new treatments for cancer and rare diseases.
Market segment debts - Oncology cell gene therapy
Poseida Therapeutics is a clinical-stage biotech company developing cell and gene therapies. This is a cutting-edge, but extremely expensive, field of science. This chart demonstrates that the company, like its peers in the sector, relies exclusively on equity capital to fund its research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Poseida Therapeutics
Poseida Therapeutics is a biotechnology company working in the cutting-edge field of cell and gene therapy for cancer. Developing such treatments is extremely expensive. This chart shows the company's reliance on debt to fund its clinical trials, a direct measure of its financial risk.
Market segment debt to market segment book capitalization - Oncology cell gene therapy
Poseida Therapeutics is a cell and gene therapy company focused on cancer treatment. This is one of the most advanced and capital-intensive fields in medicine. The chart shows how aggressively the sector uses debt for R&D, providing context for how Poseida finances its revolutionary, but very expensive, developments.
Debt to book value of all companies in the market
Poseida Therapeutics, a pioneer in cell and gene therapy, is pursuing extremely expensive and cutting-edge research. This chart, showing the market's overall debt burden, allows for an assessment of financial risk. It helps understand how the company's capital raising strategy aligns with the high standards and risks of the innovative biotech sector.
P/E of the company, segment and market as a whole
P/E - Poseida Therapeutics
Poseida Therapeutics is a biotech company developing next-generation cell and gene therapies using its cutting-edge technologies. This chart shows how investors value its scientific platform. The valuation is based on the potential of its technologies to create safer and more effective treatments for cancer and rare diseases.
P/E of the market segment - Oncology cell gene therapy
The cell therapy being developed by Poseida is the future of cancer treatment. This chart shows the average valuation for biopharmaceutical companies. It helps us understand that Poseida, with its cutting-edge genetic engineering technologies, is valued as a scientific platform whose value is based on investors' faith in its long-term potential.
P/E of the market as a whole
Poseida Therapeutics is a biotech company developing cell and gene therapies. Its valuation is a pure bet on its scientific platform. It has no connection to the general economic cycles depicted by this chart. Poseida's value is determined solely by the success or failure of its clinical trials.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Poseida Therapeutics
This chart from Poseida Therapeutics, a cell and gene therapy company, shows market expectations for its clinical developments. It reflects investor confidence in the potential of its unique technologies to create safer and more effective treatments for cancer and rare diseases.
%20P%2FE%20Poseida%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Poseida-Therapeutics&v=1772630369290 "Chart of the company's future (projected) P/E Poseida Therapeutics")
Future (projected) P/E of the market segment - Oncology cell gene therapy
Poseida Therapeutics is a clinical-stage biopharmaceutical company developing next-generation cell and gene therapies with a focus on oncology and rare diseases. This chart shows forecasts for the biotech sector. This helps compare how the market values Poseida's advanced yet complex technologies, including non-viral gene delivery methods.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-cell-gene-therapy&v=1772630369318 "Future (projected) P/E graph of the market segment - Oncology cell gene therapy")
Future (projected) P/E of the market as a whole
Poseida Therapeutics, Inc. is a biotechnology company focused on cell and gene therapy, one of the most advanced fields in medicine. A company's valuation is a bet on the future. This chart shows how willing investors are to fund fundamental scientific research that may only bear fruit years down the road.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772630369352 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Poseida Therapeutics
Poseida Therapeutics is a biopharmaceutical company developing next-generation cell and gene therapies for cancer and rare diseases. Its financial results are based on R&D losses. This chart illustrates the massive investments required to create cutting-edge therapeutic platforms.
Profit of companies in the market segment - Oncology cell gene therapy
Poseida Therapeutics is a biotech company developing next-generation cell and gene therapies for cancer. This sector revenue chart demonstrates how rapidly these breakthrough technologies are advancing. Their platforms are aimed at creating safer and more effective treatments that can help patients with the most severe forms of cancer.
Overall market profit
Poseida Therapeutics develops next-generation cell and gene therapies for cancer and rare diseases. This is one of the most advanced fields in medicine. Funding for such breakthrough but risky technologies is highly dependent on investor risk appetite, which typically increases during periods of rising corporate profits, as shown in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Poseida Therapeutics
Poseida Therapeutics is a biotech company developing next-generation cell and gene therapies for cancer and rare diseases. Its platform aims to create safer and more effective treatments. This chart summarizes analyst opinions on the potential of its breakthrough technologies and progress in clinical trials.
%20profit%20of%20the%20company%20Poseida%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Poseida-Therapeutics&v=1772630369506 "Graph of future (projected) profit of the company Poseida Therapeutics")
Future (predicted) profit of companies in the market segment - Oncology cell gene therapy
Poseida Therapeutics is a biotech company developing next-generation cell and gene therapies for cancer and rare diseases. The company's value lies in its technology platforms. This biotech chart reflects investors' overall belief in the potential of genetic engineering and their willingness to fund companies working at the forefront of science.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-cell-gene-therapy&v=1772630369536 "Graph of future (predicted) profits of companies in a market segment - Oncology cell gene therapy")
Future (predicted) profit of the market as a whole
Poseida Therapeutics develops cell and gene therapies. This is cutting-edge science, requiring massive investment. This graph, reflecting general economic expectations, influences investor willingness to invest in long-term, high-risk, but potentially revolutionary biotech companies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772630369555 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Poseida Therapeutics
Poseida Therapeutics is a biotech company developing next-generation cell and gene therapies for cancer and rare diseases. Despite the lack of revenue, this chart is crucial. It shows how investors view its cutting-edge scientific platform and the enormous potential for future revenue from its breakthrough treatments.
P/S market segment - Oncology cell gene therapy
Poseida Therapeutics develops next-generation cell and gene therapies for cancer and rare diseases. The company's valuation is based on the potential of its advanced technology platforms. This chart shows the average valuation in the sector, allowing investors to understand the high expectations for Poseida's innovative approach to creating living medicines.
P/S of the market as a whole
Poseida Therapeutics is a biotech company developing next-generation cell and gene therapies for the treatment of cancer and rare diseases. This chart, which reflects revenue estimates for traditional companies, highlights that Poseida's value stems from investors' faith in its cutting-edge scientific platforms, which could lead to breakthrough treatments.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Poseida Therapeutics
Poseida Therapeutics is a biotech company developing next-generation cell and gene therapies for cancer and rare diseases. Its platforms have the potential to create breakthrough drugs. This chart reflects investor confidence in the long-term potential of its technologies, which could be safer and more effective.
%20P%2FS%20Poseida%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Poseida-Therapeutics&v=1772630369650 "The graph of the company's future (projected) P/S Poseida Therapeutics")
Future (projected) P/S of the market segment - Oncology cell gene therapy
Poseida Therapeutics is a clinical-stage biopharmaceutical company developing cell and gene therapies for the treatment of cancer and rare genetic diseases. This chart shows the average estimated future sales in the gene therapy sector. It helps understand how highly the market values Poseida's advanced drug discovery technologies.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-cell-gene-therapy&v=1772630369696 "Future (projected) P/S market segment graph - Oncology cell gene therapy")
Future (projected) P/S of the market as a whole
Poseida Therapeutics is a biotechnology company developing next-generation cell and gene therapies for the treatment of cancer and rare diseases. The chart below shows how the market views its revenue growth prospects. The company's innovative platforms could lead to safer and more effective treatments.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772630369710 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Poseida Therapeutics
This chart shows the revenue of Poseida Therapeutics, a clinical-stage biopharmaceutical company specializing in cell and gene therapy for cancer. Its revenue is generated through upfront and milestone payments from major pharmaceutical partners, reflecting the progress of its cutting-edge technologies.
Sales of companies in the market segment - Oncology cell gene therapy
Poseida Therapeutics is a biotechnology company developing next-generation cell and gene therapies for cancer and rare diseases. This chart illustrates the growth of the gene therapy market. The company's advanced technologies, such as non-viral gene delivery, can make therapy safer and more accessible, which is key to the development of the entire sector.
Overall market sales
Poseida Therapeutics is a biotech company developing cell and gene therapies for cancer treatment. Its market capitalization depends on scientific progress. The overall economic situation, reflected in this chart, influences investor willingness to fund cutting-edge and capital-intensive oncology research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Poseida Therapeutics
Poseida Therapeutics is a cutting-edge biotech company developing cell and gene therapies for the treatment of cancer and rare diseases. Future revenue depends on the success of its advanced platforms. The chart reflects analysts' confidence in the breakthrough potential of its developments.
%20sales%20of%20the%20company%20Poseida%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Poseida-Therapeutics&v=1772630370094 "Schedule of future (projected) sales of the company Poseida Therapeutics")
Future (projected) sales of companies in the market segment - Oncology cell gene therapy
Poseida Therapeutics is a biotechnology company developing next-generation cell and gene therapies for the treatment of cancer and rare diseases. The company uses proprietary, cutting-edge technologies to create safer and more effective drugs. This chart shows the forecast for the entire oncology market, where gene therapies like Poseida's are at the forefront of science.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-cell-gene-therapy&v=1772630370125 "Schedule of future (projected) sales of companies in the market segment - Oncology cell gene therapy")
Future (projected) sales of the market as a whole
Poseida Therapeutics is a clinical-stage biotech company developing cell and gene therapies for cancer and rare diseases. Its valuation is based on the potential of its cutting-edge technologies. This graph, reflecting investors' risk appetite, impacts the availability of the massive capital required to advance such complex treatments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772630370160 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Poseida Therapeutics
Poseida Therapeutics is a biotech company developing next-generation cell and gene therapies for cancer. Being in the clinical stage, it incurs significant R&D expenses. This chart shows its net losses—investments in developing safer and more effective treatments that can overcome the limitations of existing therapies.
Market segment marginality - Oncology cell gene therapy
Poseida Therapeutics is a clinical-stage biotechnology company developing next-generation cell and gene therapies for the treatment of cancer and rare diseases. Profitability is a long-term goal. This chart reflects investments in their cutting-edge scientific platforms. Investors evaluate it in the context of the potential for creating breakthrough treatments.
Market marginality as a whole
Poseida Therapeutics is a biotechnology company developing next-generation cell and gene therapies for the treatment of cancer and rare diseases. Their technologies are aimed at improving the safety and efficacy of treatments. This overall profitability schedule is not important to them. Their future depends solely on the success of their scientific platform and clinical development.
Employees in the company, segment and market as a whole
Number of employees in the company Poseida Therapeutics
Poseida Therapeutics is a biotechnology company developing cutting-edge cell and gene therapies. Its growing team consists of scientists and manufacturing specialists. This chart reflects the company's significant investments in its sophisticated technology platforms and the development of its own manufacturing capabilities.
Share of the company's employees Poseida Therapeutics within the market segment - Oncology cell gene therapy
Poseida Therapeutics is at the forefront of cell and gene therapy, developing treatments using its advanced gene editing technologies. This chart shows the company's share of the unique scientific talent in this complex field, demonstrating its scientific potential to create breakthrough medicines.
Number of employees in the market segment - Oncology cell gene therapy
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing next-generation cell and gene therapies. This chart shows employment trends in this cutting-edge field of medicine. The growing number of scientists here signals progress in developing safer and more effective CAR-T therapies for the treatment of cancer and rare diseases.
Number of employees in the market as a whole
Poseida Therapeutics develops cell and gene therapies for cancer treatment. This cutting-edge field requires significant investment. General economic stability, illustrated by this chart, influences investor willingness to invest in high-risk but potentially breakthrough biotech companies like Poseida.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Poseida Therapeutics (PSTX)
Poseida Therapeutics is a biotech company developing cell and gene therapies. This is one of the most complex and capital-intensive areas of R&D. The chart shows that the company's market value is a valuation of its scientific platform. Every employee is a highly qualified scientist, and the high market value per employee reflects investors' belief that their technology will lead to a breakthrough in the treatment of cancer or genetic diseases.
%20of%20the%20company%20Poseida%20Therapeutics%20(PSTX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Poseida-Therapeutics-PSTX&v=1772630370329 "Chart of market capitalization per employee (in thousands of dollars) of the company Poseida Therapeutics (PSTX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
Poseida Therapeutics is a biotech company developing next-generation cell and gene therapies for cancer. Its value is based on its advanced technology platforms. This chart demonstrates the very high market valuation of its scientific developments and intellectual property, based on its small team of scientists.
%20by%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-cell-gene-therapy&v=1772630370344 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology cell gene therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Poseida Therapeutics is a biopharmaceutical company developing next-generation cell and gene therapies. The chart illustrates the valuation of its cutting-edge technologies. The very high market capitalization per employee reflects the enormous potential of their complex and innovative platforms for treating cancer and rare diseases.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772630370369 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Poseida Therapeutics (PSTX)
Poseida Therapeutics is a clinical-stage biotech company developing advanced cell and gene therapies (CAR-T) for cancer treatment. This R&D is at the forefront of science. This chart shows the cost of these technologies: the enormous investment required for each scientist working on creating "living drugs."
%20Chart%20Poseida%20Therapeutics%20(PSTX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Poseida-Therapeutics-PSTX&v=1772630370385 "Company Profit Per Employee (in thousands of dollars) Chart Poseida Therapeutics (PSTX)")
Profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
Poseida Therapeutics is a clinical-stage biotechnology company developing cutting-edge cell and gene therapies. This is one of the most complex and expensive areas of R&D. This metric (loss per employee) reflects the company's massive investment in research and clinical trials.
%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-cell-gene-therapy&v=1772630370389 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Poseida Therapeutics is a clinical-stage biotech company specializing in cell and gene therapy (CAR-T, liver gene therapy). It's an R&D company. The company is not profitable. This chart shows its capital burn rate: operating loss per research team.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772630370423 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Poseida Therapeutics (PSTX)
Poseida Therapeutics is a biotech company developing cell and gene therapies for the treatment of cancer and rare diseases. This chart reflects the progress of monetizing its advanced platforms. Revenue growth at this stage is likely due to upfront payments from major pharmaceutical industry partners.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Poseida-Therapeutics-PSTX&v=1772630370442 "Sales chart per company employee Poseida Therapeutics (PSTX)")
Sales per employee in the market segment - Oncology cell gene therapy
Poseida (PSTX) is a cutting-edge company developing cell (CAR-T) and gene therapies, some of the most complex cancer treatments. This chart shows how productive their R&D team is. It measures revenue (from partnerships with Big Pharma) per scientist, reflecting the value of their scientific platform.
Sales per employee for the market as a whole
Poseida Therapeutics (PSTX) is a clinical-stage biotech developing cell (CAR-T) and gene therapies. This is one of the most complex and expensive areas of R&D. The company has no commercial revenue. This chart reflects a typical R&D situation: the research staff generates data and patents, but not operating income.
Short shares by company, segment and market as a whole
Shares shorted by company Poseida Therapeutics (PSTX)
Poseida Therapeutics is a biotech company developing cutting-edge cell and gene therapies. This is an extremely expensive and risky field. The bearish sentiment shown by this chart is a bet that its complex treatments will prove unsafe or ineffective in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Poseida-Therapeutics-PSTX&v=1772630370596 "Short Shares Chart for the Company Poseida Therapeutics (PSTX)")
Shares shorted by market segment - Oncology cell gene therapy
Poseida Therapeutics (PSTX) is at the forefront of the fight against cancer, developing cutting-edge cell and gene therapies, including CAR-T. This is one of the most complex areas of biotech. This chart reflects the overall investor pessimism about the entire cell therapy sector. It shows how the market as a whole doubts the safety, scalability, and commercial viability of these methods.
Shares shorted by the overall market
Poseida is a cutting-edge biotech company (gene therapy). It requires extremely complex and expensive R&D. This chart illustrates the general market "fear." When investors panic, they are unwilling to fund the longest and riskiest scientific projects. They see their cash being burned through and sell off their shares.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Poseida Therapeutics (PSTX)
Poseida Therapeutics is a biotech company developing allogeneic CAR-T therapies for cancer treatment. It's at the cutting edge of oncology. This chart measures the market's "temperature," showing when the stock is "overheated" (above 70) in anticipation of a breakthrough in trials or "oversold" (below 30) due to delays or setbacks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Poseida-Therapeutics-PSTX&v=1772630370631 "RSI 14 indicator chart for the company's stock Poseida Therapeutics (PSTX)")
RSI 14 Market Segment - Oncology cell gene therapy
Poseida Therapeutics is a biotech company developing cell (CAR-T) and gene therapies. Their uniqueness lies in their non-viral delivery platform, which is considered safer. This chart reflects the general sentiment in the genetic engineering sector. It helps assess how overheated this futuristic biotech segment is.
RSI 14 for the overall market
Poseida (PSTX) is a biotech R&D company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PSTX (Poseida Therapeutics)
Poseida (PSTX) is a biotech company developing cell (CAR-T) and gene therapies, leveraging its unique technologies to improve safety and efficacy. This chart shows the average price target. It reflects analysts' confidence in this advanced platform and their expectations for clinical trial data, particularly in oncology.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PSTX-Poseida-Therapeutics&v=1772630370652 "A chart showing analyst consensus forecasts for the expected stock price. PSTX (Poseida Therapeutics)")
The difference between the consensus estimate and the actual stock price PSTX (Poseida Therapeutics)
Poseida (PSTX) is a biotech company developing cell and gene therapies (CAR-T) using a non-viral delivery technology (piggyBac). This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their faith in this cutting-edge R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PSTX-Poseida-Therapeutics&v=1772630370655 "A chart showing the difference between the consensus forecast and the actual stock price. PSTX (Poseida Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Oncology cell gene therapy
Poseida is an R&D biotech company "on steroids," developing cell (CAR-T) and gene therapies. The company is focusing on "next-generation" R&D. This chart displays analysts' overall expectations for the *entire* "cell-oncotherapy" sector. It shows whether experts believe a breakthrough in cancer treatment is possible.
Analysts' consensus forecast for the overall market share price
Poseida Therapeutics (PSTX) is a biopharmaceutical company at the forefront of cell therapy. They are developing a non-viral delivery system (piggyBac) and CAR-T therapy for cancer. This R&D is highly speculative. This chart shows the overall risk appetite, reflecting the willingness of investors to fund breakthrough, but extremely expensive, R&D platforms.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Poseida Therapeutics
Poseida is a pioneer in cell therapy. Their signature feature is a non-viral (piggyBac) DNA delivery system, which they claim can deliver large genes (for CAR-T) more safely and effectively than older viruses. This graph is a clear indicator of their deep science. It reflects their (very long) R&D journey and their partnerships (for example, with Astellas).
AKIMA Market Segment Index - Oncology cell gene therapy
Poseida Therapeutics (PSTX) is a cell and gene therapy company. They are at the forefront of medicine, developing CAR-T therapy (for cancer) and gene therapy (for liver diseases). This chart compares their composite index to the sector, showing how their high-tech R&D platform outperforms the competition.
The AKIM Index for the overall market
Poseida Therapeutics is a biotech company using genetic engineering (piggyBac, Cas-CLOVER) to create cell and gene therapies. This chart, which reflects the market average, is an indicator of risk appetite. It shows the macro backdrop critical to funding this cutting-edge platform.
